1. Welte K, Platzer E, Lu L, et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci USA 1985; 82:1526-1530.

2. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996; 88:1907-1929.

3. Patterson KL, Masuda SY, Brown SL. Safety profile of filgrastim (r-metHuG-CSF). In: Morstyn G, Dexter TM, Foote MA, ed., Filgrastim (r-metHuG-CSF) in Clinical Practice, 2nd ed. Totowa, NJ: Humana. 1998:583-602.

4. stRice L, Nichol JL, McMillan R, Roskos LK, Bacile-M. Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. Am J Hematol 2001; 68:210-214.

5. Reuss-Borst MA, Muller CA, Waller HD. The possible role of G-CSF in the pathogenesis of Sweet's syndrome. Leuk Lymphoma 1994; 15:261-264.

6. Bleomycin at Accessed 12 May 2003.

7. Adach K, Suzuki M, Sugimoto T, et al. Granulocyte colony-stimulating factor exacerbates the acute lung injury and pulmonary fibrosis induced by intratracheal administration of bleomycin in rats. Exp Toxicol Pathol 2002; 53:501-510.

8. Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol 191; 65:81-94.

9. Takamizawa A, Koyama S, Sato E, et al. Bleomycin stimulates lung fibroblasts to release neutrophil and monocyte chemotactic activity. J Immunol 1999; 162:6200-6208.

10. Saxman SB, Nichols CR, Einhorn LH. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. Chest 1997; 111:657-660.

11. Lei KI, Leung WT, Johnson PJ. Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma. Br J Cancer 1994; 70:1009-10013.

12. Sargramostim. http:/ Accessed 12 May 2003.

13. Stanworth SJ, Bhavnani N, Chatopadhya C, Miller H, Swinson DR. Treatment of Felty's syndrome with the haemopoietic growth factor granulocyte colony-stimulating factor (G-CSF). Q J Med 1998; 91:49-56.

14. Lehrnbecher T, Welte K. Haematopoietic growth factors in children with neutropenia. Br J Haematol 2002; 116:28-56.

15. Medlock ES, Kaplan DL, Cecchini M. Ulich TR, delCastillo J, Andresen J. Granulocyte colony-stimulating factor crosses the placenta and stimulates fetal rat granulopoiesis. Blood 1993; 81:91-92.

16. Novales JS, Salva AM, Modanlou HD, et al. Maternal administration of granulocyte-stimulating factor improves neonatal rat survival after a lethal group B streptococcal infection. Blood 1993; 15:81:923-927.

17. Calhoun DA, Donnelly WH, Du Y, Dame JB, Li Y, Christensen RD. Distribution of granulocyte colony-stimulating factor (G-CSF) and G-CSF-receptor mRNA and protein in the human fetus. Pediatr Res 1999; 46:333-338.

18. Kostmann R. Infantile genetic agranulocytosis. Acta Pediatr Scand 1956; 45:1-78.

19. Horwitz M, Benson KF, Person RE, et al. Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoesis. Nature Genet 1999; 23:433-436.

20. Dale DC, Person RE, Bolyard AA, et al. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood 2000; 96:2317-2322.

21. Germeshausen M, Schulze H, Ballmaier M, et al. Mutations in the gene encoding neutrophil elastase (ELA2) are not sufficient to cause the phenotype of congenital neutropenia. Br J Haematol 2001; 115:1-4.

22. Dong F, Russel KB, Tidow N, et al. Mutations in the gene for the granulocyte-colony stimulating factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med 1995; 333:487-493.

23. Tidow N, Pilz C, Teichmann B, et al. Clinical relevance of point mutations in the cytoplasmatic domain of the granulocyte-colony stimulating factor gene in patients with severe congenital neutrope-nia. Blood 1997; 88:2369-2375.

24. Tschan CA, Pilz C, Zeidler C, et al. Time course of increasing numbers of mutations in the granulocyte colony-stimulating factor receptor gene in a patient with congenital neutropenia who developed leukemia. Blood 2001; 97:1882-1884.

25. Bernard T, Gale R, Evans J, et al. Mutations of the granulocyte-colony stimulating factor receptor in patients with severe congenital neutropenia are not required for transformation to acute myeloid leukaemia and may be a bystander phenomenon. Br J Haematol 1998; 101:141-149.

26. Welte K, Boxer L. Severe chronic neutropenia: pathophysiology and therapy. Semin Hematol 1997; 34:267-278.

27. Bux J, Behrens G, Jaeger G, et al. Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases. Blood 1998; 91:181-186.

28. Bonilla M, Dale D, Zeidler C, et al. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congential neutropenias. Br J Hematol 1994; 88:723-730.

29. Bonilla M, Gillio A, Ruggeiro M, et al. Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med 1989; 320:1574-1580.

30. Welte K, Zeidler C, Reiter A, et al. Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood 1990; 75:1056-1063 .

31. Zeidler C, Welte K, Barak Y, et al. Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemia transformation. Blood 2000; 95:1195-1198.

32. Rappeport J, Parkman R, Newburger P, et al. Correction of infantile granulocytosis (Kostmann syndrome) by allogeneic bone marrow transplantation. Am J Med 1980; 68:605-609.

33. Rosen R, Kang S. Congenital agranulocytosis terminating in acute myelomonocytic leukemia. J Pediatr 1979; 94:406-408.

34. Oilman P, Jackson D, Guild H. Congenital agranulocytosis: prolonged survival and terminal acute leukemia. Blood 1970; 36:576-585.

35. Freedman MH, Alter BP. Risk of myelodysplastic syndrome and acute myeloid leukemia in congenital neutropenias. Semin Hematol 2002; 39:128-133.

36. Yakisan E, Schirg E, Zeidler C, et al. High incidence of significant bone loss in patients with severe congenital neutropenia (Kostmann's syndrome). J Pediatr 1997; 131:592-597.

37. Leale M. Recurrent furunculosis in an infant showing an unusual blood picture. JAMA 1910; 54:1854-1855.

38. Dale D, Bonilla M, Davis M, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (G-CSF) for treatment of severe chronic neutropenia. Blood 1993; 81:2496-2502.

39. Dale DC, Bolyard AA, Aprikyan A. Cyclic neutropenia. Semin Hematol 2002; 39:89-94.

40. Milkovitch G, Moleski RJ, Reitan JF, et al. Comparative safety of filgrastim versus sargramostim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy 2000, 20:1432-1440.

0 0

Post a comment